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Abstract 
Thymosin alpha 1 (Tα1) has immunomodulatory and anti-tumor effects in patients and 
has been commercialized in worldwide. An innovative technique is therefore impending 
to achieve high-yield expression and purification of Tα1 to meet the increasing require-
ments for clinical applications. Tα1 can enhance T cells, dendritic cells and antibody re-
sponses, and also augment an anti-tumor immune response. In the current study, we 
developed a novel technique to produce Tα1 concatemer and investigated its capability 
in anti-tumor immunotherapy. We expressed the recombinant 2×Tα1 concatemer protein 
(Tα1② protein) in Escherichia coli. The purity of Tα1② was higher than 95% as assessed 
by HPLC analysis. In vitro, Tα1② could stimulate the proliferation of mouse splenic 
lymphocyte, and increase the apoptosis of tumor cell lines. In vivo, Tα1② significantly 
inhibited the tumor growth in B16 tumor-bearing mice. Compared with Tα1, the Tα1② 
is of more effective bioactivity than Tα1. The purified Tα1② is a promising substitute for 
synthetic Tα1 because of its potent anti-tumor effects. We concluded that the expression 
system for Tα1 concatemer was constructed successfully, which could serves as a highly 
efficient tool for the production of large quantities of the highly active protein. 
Key words: Thymosin alpha 1; concatemer; protein expression; purification; tumor suppression 
Introduction 
Tα1 is a heat stable, acidic polypeptide consist-
ing of 28 amino acid residues with a molecular weight 
of 3108 Da and an isoelectric point of pH4.2 (1). As a 
biological response modifier, Tα1 enhances immune 
response  and  promotes  specific  lymphocyte  func-
tions,  including  lymphoproliferative  responses  to 
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mitogens, maturation of T-cells (2), antibody produc-
tion, and T-cell-mediated cytotoxicity (3-5). It can an-
tagonize  apoptosis  of  T  cells  induced  by  dexame-
thasone or CD3  monoclonal antibody (6) or sera of 
tumor-bearing mice (7). Tα1 also can stimulate lym-
phokine production of IFN-γ, IFN-α, IL-2, and mac-
rophage migration inhibitory factor (MIF) (8). It also is 
capable  to  activate  infected  dendritic  cells  through 
toll-like-receptor  signaling.  Furthermore,  Tα1  can 
significantly inhibit proliferation and induce apopto-
sis in many tumor cell lines (9-10). Previous studies 
showed that Tα1 could reduce tumor size in mice (11), 
and partly restore cellular immunity (12).  
Thymosin α1 belongs to the thymus extract de-
nominated by thymosin fraction5 (TF5) which shows 
immunoregulatory properties (13). Tα1 is an immune 
modifier  that  can  trigger  maturational  events  in 
lymphocytes, augment T-cell function, and promote 
reconstitution of immune defects (14). Because of the 
previously  reported  potential,  Tα1  has  been  used 
worldwide for the treatment of a number of diseases 
including  immunodeficiencies  (15-16),  malignancies 
(17), and infections such as HBV(18), HIV (19), either 
in stand-alone therapy or in conjunction with IFN-α 
(20). Recently, Tα1 has also been used as an adjuvant 
for vaccines against influenza and hepatitis (21). 
It  is  widely  accepted  that  Tα1  affects  tumor 
bearing  hosts  by  activating  infected  dendritic  cells 
through toll-like-receptor signaling, augmenting spe-
cific lymphocyte functions, increasing the expression 
of tumor and MHC-I antigens, and enhancing their 
immune responsiveness. Thus, Tα1 can influence the 
inflammation balance. In vivo, high doses of Tα1 can 
improve  anti-tumor  efficacy  of  chemo- 
immunotherapy against B16 melanoma and increase 
the average survival time of treated mice (22). More-
over, clinical trials using Tα1 in the treatment of pa-
tients with cancer indicate that this agent is nontoxic 
(23-24).  Tα1  can  cause few  side  effects  and  has  the 
benefit of arresting neurotoxicity induced by chemo-
therapy (25). These reports all indicate the safe appli-
cations of Tα1 in future clinical practice for malignant 
tumor patients. 
Although the Tα1 has been successfully applied 
in clinical trials, but the high costs greatly limited its 
clinical  use.  Increasing  therapeutic  applications  for 
Tα1  has  attracted  rising  interests  in  optimizing 
methods for its production and purification. Recom-
binant  DNA  techniques  has  been  applied  in  many 
laboratories to produce Tα1 including the expression 
of Tα1 as fusion proteins (26). The shortcoming of this 
method is that the fusion protein must be removed 
because  the  peptide  might  be  inactive  (27)  and  the 
bioactivities of the fusion proteins were lower than 
that of Tα1 (28). Tα1 in concatemer form expressed as 
a His6 tagged fusion protein was also studied (29-30). 
Data showed this kind of fusion protein exhibited a 
weeker  stimulation  on  mice  lymphocytes  prolifera-
tion  than  synthetic  Tα1  (30).  Furthermore,  His6  tag 
sequence  may  not  be  safe  and  may  lead  to  some 
problems in clinical research. On the other hand, the 
affinity purification of the protein by His6 tag is costly. 
The  Tα1  concatemer  protein  was  also  expressed  in 
inclusion  body  form  and  had  to  be  cleaved  by  hy-
droxylamine to release the active Tα1 monomer (27). 
Obviously,  the  current  techniques  available  are  not 
suitable for large-scale manufacture  of Tα1 and the 
activity of this protein in vivo are also questioned.  
In this study, a recombinant gene encoding re-
combinant  2×Thymosin  alpha  1  tandem  repeats 
(Tα1②)  was  synthesized,  inserted  into  expression 
vector pET-22b (pET-Tα1②) and expressed in E.coli. 
We have developed an economic and scalable purifi-
cation  protocol  to  produce  the  recombinant  Tα1② 
protein with the final yielding ratio of 4.5mg purified 
protein out of per gram of cell paste.  
Remarkably, the bioactivity of the protein was 
more effective than that of synthetic Tα1. MTT assay 
shows high dose Tα1 can inhibit B16 cell proliferation 
and induce cell apoptosis, which prompted us to in-
vestigate the anti-tumor efficacy of Tα1 in vivo. We 
administered high dose of Tα1 monomer or Tα1② to 
B16  bearing  melanoma  C57  mice,  and  found  that 
Tα1② treatments (8mg/kg and 16mg/kg) caused the 
conspicuous  regression  of  subcutaneous  tumor. 
Tα1② had an inhibitory effect on the growth of sev-
eral tumor cell lines which is even more significant 
than Tα1 from synthetic. All the results suggested that 
this strategy for production of Tα1 was effective and 
simple. 
Materials and Methods 
Materials  
Expression  vectors  pET-22b  and  E.  coli  BL21 
were kept in our laboratory. Thymosin 2 concatemer 
gene was synthesized by Beijing AuGCT Company. 
The  synthetic  Tα1  was  purchased  from  BACHEM 
Company  (catalogue  no.  62304-98-7).  The  anti-  Tα1 
antibody (catalogue no. ab55635) was purchased from 
Abcam Company. The secondary goat anti-mice IgG 
antibody  conjugated  with  HRP  (catalogue  no. 
Zb-2305)  was  purchased  from  Beijing  Zhongshan 
Company. The TUNEL detection kit was purchased 
from KeyGEN Company (catalogue no. KGA702). 
Construction of Recombinant plasmid pET- Tα1② 
Tα1② gene was designed and synthesized. Gly Int. J. Biol. Sci. 2011, 7 
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and  Ser  as  a  linker  were  inserted  between  the  two 
monomer  sequences  of  Tα1.  The  synthesized  se-
quences  is  as  follows:  Sense  strand, 
5’-CATATGTCTGATGCAGCGGTTGACACCAGCT
CGGAAATCACCACCAAAGACCTGAAAGAGAA
GAAAGAGGTGGTGGAAGAAGCGGAGAACGGA
TCCAGCGATGCGGCGGTTGACACCAGCTCGGA
AATCACCACCAAAGACCTGAAAGAGAAGAAA
GAGGTGGTGGAAGAAGCGGAGAACTAGAAGCT
T-3’ (NdeⅠand Sal I restriction site was underlined). 
The  synthesized  gene  was  cloned  into  pET-22b  (+) 
vector.  The  recombinant  plasmid  was  identified  by 
DNA  sequencing.  E.  coli  strain  BL21  (DE3)  was 
transformed  with  the  correct  recombinant  plasmid 
containing  the  Tα1②  gene.  The  expression  of  the 
Tα1② gene was driven by a T7 promoter, which can 
be regulated by inducing the culture with isopropyl 
β-D-thiogalactopyranoside  (IPTG)  thereby  allowing 
high level of expression of the Tα1② gene. 
Expression of Tα1②  
The recombinant plasmid containing the Tα1② 
gene  was  transformed  into  E.  coli.  BL21(DE3)  and 
plated  on  Luria  Broth  (LB)-Agar,  containing 
100μg/ml ampicillin. After an overnight incubation at 
37℃, a single colony was used to inoculate 10 ml of LB 
media containing 100μg/ml ampicillin and incubated 
overnight  at 37℃  with  shaking at  200  rpm.  Then 3 
milliliters of culture was transferred to 300ml fresh LB 
medium with 100μg/ml ampicillin in a 500ml shake 
Task. The culture was then induced after reaching an 
optical  density  of  0.6  at  600  nm  by  the  addition of 
IPTG to a final concentration of 0.5 mM and cultured 
at 37℃, 200 rpm for 4h. Samples were collected at 1, 2, 
3 and 4h respectively. Electrophoresis of the expres-
sion samples and the molecular marker were carried 
out on SDS-PAGE gels, stained with coomassie bril-
liant  blue  (CBB)  G-250.  The  optimal  induction  time 
was  confirmed  by  analysing  the  protein  expression 
level at different times. 
The culture was centrifuged at 10,000 rpm for 15 
min at 4℃. The supernatant was carefully removed, 
and the cell pellet was washed by gently suspending 
in  lysis  buffer  (20mM  Tris-HCl,  150mM  NaCl,  and 
1mM EDTA, pH 8.5). The washed cell mass (10 g) was 
collected by centrifuging at 10,000 rpm, 4℃ for 15 min 
and stored at -20℃. 
Purification of Tα1② 
Ten grams (wet weight) of pellet was suspended 
in 100 ml of lysis buffer in a beaker maintained on ice. 
The  cells  were  disrupted  with  a  sonicator  pro-
grammed for 25 min of 5 sec on and 10 sec off. The 
sonicate was then centrifuged at 14,000 rpm at 4℃ for 
15 min. The supernatant was transferred to a clean 
tube without disturbing the pellet. Ammonium sul-
fate was added to the cleared lysate to 60% saturation 
and kept for 60min at 4℃. The supernatant collected 
by centrifugation at 10,000 rpm for 20 min at 4℃ was 
loaded onto a hydrophobic column at room temper-
ature. The column was equilibrated with ammonium 
sulfate  of  60%  saturation  and  eluted  with  a  linear 
gradient of ammonium sulfate from 60% to 0%. Then 
the  eluted  fractions  were  collected  and  dialyzed 
against  buffer  A  (20mM  citric  acid-  citrate,  1mM 
EDTA, pH 5.0) thoroughly. The resulting solution was 
applied  to  Q  Sepharose  fast  flow  column 
pre-equilibrated with buffer A and eluted with a lin-
ear gradient of NaCl from 0 to 1M in buffer B (20mM 
citric  acid-  citrate,  1mM  EDTA,  1  mol/L  NaCl,  pH 
5.0). The protein was monitored by measuring the UV 
absorbency  at  215  nm.  The  eluted  fractions  were 
pooled and dialyzed against 20mM phosphate buff-
er(pH  7.2)  at  4℃  with  frequent  buffer  changes  and 
then stored at -20℃. 
Western-blot analysis 
For western blots, after electrophoresis the sam-
ples  and  molecular  weight  standards  were  electro-
phoretically  transferred  to  an  NC  membrane.  The 
membrane was probed with a mouse anti-human Tα1 
monoclonal antibody (Abcam, catalogue no. ab55635) 
followed by incubation with specific HRP-conjugated 
goat  anti-mice  IgG  (Beijing  Zhongshan  Company, 
catalogue no. Zb-2305). The immunoreactive protein 
was visualized with an enhanced chemiluminescence, 
(Nanjing keygen Company, catalogue no. KGP1123). 
Proliferation assay of Tα1② protein on mouse 
splenic lymphocytes 
The  proliferation  response  of  splenocytes  was 
determined  by  MTT  assay.  Spleens  were  removed 
from  6~8-week-old  BALB/c  mice  and  dispersed 
through nylon mesh to generate a single-cell suspen-
sion. The lymphocytes were separated by lymphocyte 
separating medium and collected by centrifugation at 
1000 rpm for 10 min. The cell pellet was re-suspended 
in RPMI 1640 medium. One hundred microliter of the 
suspension was seeded in each well of 96 well plates 
at a concentration of 4×106 cells /ml and incubated in 
RPMI 1640 medium with 2.5 μg/ml concanavalin A 
(ConA) for 6 hours. After incubation, 90 μl of Tα1② 
protein that had been previously diluted with RPMI 
1640 culture medium was added to all but the control 
wells. The synthetic Tα1 and RPMI 1640 culture me-
dia  were  used  as  positive  and  negative  controls  (3 
parallel wells). After 66h incubation at 37℃, 20 μl of 
MTT (0.5 mg/ml) solution was added to each well, Int. J. Biol. Sci. 2011, 7 
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and  the  microplates  were  incubated  for  4  hours  at 
37℃.  After  incubation,  the  plates  were  centrifuged 
(2,000 rpm, 25℃, 10 minutes). The supernatants were 
removed, and 100 μl of dimethyl sulfoxide (DMSO) 
was added to each well and incubated for 10 minutes 
at room temperature. After incubation, the solubilized 
reduced MTT was measured colorimetrically at 570 
nm  using  a  Benchmark  microculture  plate  reader 
(Bio-Rad,  USA).  The  optical  densities  results  were 
used for calculate growth rate.  
 Growth rate (%) = OD sample / OD control 100% 
Inhibitory effect of Tα1② on tumor cell lines  
HL60,  M1,  S180,  B16  and  Hep-G2  cells  were 
cultured in RPMI1640 medium containing 10% fetal 
bovine serum at 37℃ in a humidified 5% CO2 incu-
bator and regularly passaged. We harvested the cells 
when  they  are  in  the  exponential  phase  of  growth. 
Cells were re-suspended and diluted to 1 × 104 cells 
per  ml  in  RPMI  1640  culture  medium.  Then  100μl 
(5×103cells) of diluted cells was seeded into each well. 
After incubation at 37℃ for 6h, 100 μl of Tα1② pro-
tein  of  different  dilutions  (37.5μg/ml,  75μg/ml, 
150μg/ml,  300μg/ml  and  600μg/ml)  was  added  to 
the plate. The synthetic Tα1 and PBS were also used 
as positive and negative controls, respectively. After 
incubation for 24 h, 20μl of MTT (0.5 mg/ml) solution 
was added to each well, and the microplate was in-
cubated  for  4  hours  at  37℃.  After  incubation,  the 
plates were centrifuged (2,000 rpm, 25℃, 10 minutes). 
The supernatants were discarded and 100μl of DMSO 
was added to each well. Then the plate was swirled 
gently for 10 min at room temperature. The absorb-
ance was read at 570 nm. The results were used for 
calculate Inhibition rate. 
Inhibition ratio (%) =(OD control-OD sample) / (OD 
control)100% 
The IC50 (the drug concentration that causes a 
50% reduction in cell proliferation) values of Tα1 and 
Tα1② were estimated from the inhibition ratios. 
Cell cycle analysis and apoptosis assays 
The  effects  of  Tα1②  on  both  cell  cycle  and 
apoptosis in B16 cells were analyzed using flow cy-
tometry. For cell cycle analysis, cells were plated into 
12-well plates. Tα1②, Tα1 (150μg/ml) and PBS (used 
as negative control) were added and kept for 16 h. 
Then the cells were collected and washed with PBS 
without Ca2+ and Mg2+ and fixed with 70% ethanol. 
Cells were re-suspended in 1× binding buffer (10 mM 
HEPES-NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2) 
and 5 μl of propidium iodide/105 cells, and incubated 
at room temperature for 15 min. Cells were acquired 
and the percentage of cells in each stage of the cell 
cycle was analyzed by flow cytometry. 
 Cells  were  plated  into  12-well  plates.  Tα1②, 
Tα1 (150μg/ml) and PBS (used as negative control) 
were added and kept for 16 h. Cells floating in the 
medium  combined  with  adherent  layer  were  tryp-
sinized  and  incubated  with  annexin 
V-FITC/propidium  iodide.  Samples  were  immedi-
ately analyzed by flow cytometry for cell cycle and 
apoptosis assays. Detection of apoptosis through an-
nexin V and PI staining was done as following: Cells 
were washed three times in PBS and re-suspended in 
binding buffer at 1 × 106 cells/ml. An aliquot of 1 × 105 
cells was stained with annexin V-FITC and PI for 15 
minutes  at  room  temperature.  Analysis  was  per-
formed  on  a  BD  FacsCalibur  flow  cytometer.  Cells 
were considered to be early apoptotic if they exhibited 
staining for annexin V. The double positive popula-
tion was considered to be in the late stage of apoptosis 
Detection of apoptotic cells by TUNEL Sections 
were  performed  with  the  Cell  Death  Detection  kit 
(KeyGEN,  China),  according  to  the  manufacturer's 
instructions. Apoptotic cells were examined with flu-
orescence  microscope.  At  400×  magnifications,  20 
visual  fields  were  randomly  selected  to  count  the 
number  of  apoptotic  cells  and  the  total  number  of 
cells, respectively. The apoptosis index (AI) = (num-
ber of apoptotic cells / number of total cells) × 100%.  
In vivo anti-tumor effect 
C57BL/6 mice were challenged subcutaneously 
with  B16  melanoma  cells  rearward,  5×105  cells  / 
mouse.  On  the  tenth  day,  after  tumors  were  larger 
than 0.01cm3 in the majority of the mice, we discarded 
the  mice  without  tumors  or  with  oversized  tumors 
and divided the others stochastically into 5 groups at 
random.  The  administration  of  drugs  began  at  the 
same day. The 5 groups were separately injected in-
traperitoneally with 150μl of saline, synthesized Tα1 
(8mg/Kg/day),  high  dose  Tα1②  (16mg/Kg/day), 
middle  dose  Tα1②(8mg/Kg/day)  and  low  dose 
Tα1②  (4mg/Kg/day).  Tumor  size  was  measured 
every 2 days or every day and calculated according to 
the  following  formula:  Tumor  size  (cm3) 
=π×length×wide2/6.  The  administration  lasted  for 
twelve days. Then the mice were sacrificed and the 
tumor tissue was dissected for body mass. The results 
were used for statistic analysis. 
Statistical analysis 
All the data were analyzed with SPSS 13.0 soft-
ware and student t-test was used. A P-value of less 
than  0.05  indicated  a  statistically  significant  differ-
ence. Int. J. Biol. Sci. 2011, 7 
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Results 
Plasmid construction and identification 
The tandem Tα1 gene of 2 repeats was synthe-
sized and cloned into pET-22b (+) plasmid (pET-22b 
-T1②) (Fig.1A). DNA sequence analysis confirmed 
that recombinant T1② gene was correct. 
Expression, Purification and Western-blot anal-
ysis of Tα1② 
The  expression  plasmid  pET22b-Ta1②  was 
transformed into E.coli BL21(DE3). Tα1②(6.3 kD) was 
expressed in soluble form with the presence of 0.5mM 
IPTG for 4 hours(Fig.1B). Tα1② was precipitated by 
ammonium  sulfate,  purified  by  hydrophobic  chro-
matography  and  anion  exchange  chromatography 
and  harvested  with  purity  over  95%  by  HPLC 
(Fig.1C). Western blot analysis confirmed that Tα1② 
could be recognized by a polyclonal antibody against 
the  human  Tα1  (Fig.1D).  This  purification  process 
resulted  in  final  yielding  ratio  as  4.5mg  purified 
Tα1②/g cell paste (Table 1). 
 
 
 
 
 
Figure 1. Plasmid construction ,Tα1② expression and purification and western blot analysis. (A) Schematic map of 
pET-22b(+)-Tα1② expression vector. (B) SDS–PAGE analysis of Tα1② expression and purification. Lane 1, molecular 
weight standards (kDa); lane 2, total cell lysate before induction; lane 3~6, total cell lysate after induction for 1, 2, 
3 and 4h; lane 7, supernatant of total cell lysate after induction; lane 8, pellet of total cell lysate after induction; 
Lane 9, supernatant after 60% (NH4)2SO4 salt fractionation; Lane 10, Phenyl column wash; Lane 11, pooled Tα1② 
eluted  from  Q-Sepharose  FF  column.  (C)  HPLC  analysis  of  purifiedTα1②.  HPLC  analyses  were  performed  on  a 
Beckman’s HPLC system. The sample (5μg) in PBS was injected onto a 7.5mm×300mm G2000SW column (TOSOH 
Corporation) at a flow rate of 0.5mL/min. Peaks were detected by monitoring at a wavelength of 215 nm. (D) De-
tection of Tα1② protein by Western blot in cell pellet and supernatant, as well as Tα1② eluted from Q-Sepharose FF 
column. 
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Table 1. Purification of Tα1② (10 g of wet cell paste) 
Purification step  Protein  
concentration 
(mg/ml) 
Volume 
(ml) 
Total protein 
(mg) 
Purity 
(%) 
 
Yield 
(%) 
 
E. coli cell lysate  9.8  105  1029  21.6  — 
Salt fractionation  2.1  95  199.5  54.2  48.6 
Phenyl Sepharose  1.2  86  103.2  65.7  30.5 
Q Sepharose  1.8  26  47  95.5  20.2 
 
 
 
Tα1② stimulated the proliferation of mouse 
splenic lymphocytes in vitro 
To examine whether Tα1② could enhance the 
proliferation  of  splenic  lymphocytes,  we  compared 
the proliferation ratio of mice lymphocytes using pu-
rified  Tα1②  and  synthetic  Tα1.  The  concentrations 
were  set  as following:  60μg/ml,  30μg/ml, 15μg/ml 
and  7.5μg/ml.  The  MTT  assay  result  showed  that 
30μg/ml synthetic Tα1 could induce significant pro-
liferation of mouse spleen lymphocytes compared to 
the control(P<0.005), whereas 7.5μg/ml Tα1②could 
induce significant proliferation (Fig.2). 
 
 
 
 
 
 
Figure 2. Tα1② protein promotes the proliferation of 
mouse  spleen  lymphocytes.  Control  group:  Cultured 
cells were exposed to 2.5μg/ml ConA only; Tα1②group: 
Cultured  cells  were  exposed  to  2.5μg/ml  ConA  and 
various  concentrations  (7.5μg/ml,  15μg/ml,  30μg/ml 
and 60μg/ml) ofTα1②;Tα1 group: Cultured cells were 
exposed to 2.5μg/ml ConA and various concentrations 
(7.5μg/ml, 15μg/ml, 30μg/ml and 60μg/ml) of Tα1. Cell 
proliferation was determined by the MTT viability assay. 
The assays were repeated in triplicate. The data are 
expressed as the mean±S.E.M. of groups consisting of 
three observations. (**P<0.005, ***P<0.001)  
 
 
Tα1② inhibited the growth of the tumor cell 
lines in vitro 
Previous studies showed that Tα1 could inhibit 
the growth of the tumor cell lines. In this study, the 
inhibition effect of Tα1② on 5 tumor cell lines was 
validated.  After  24 h  of  treatment  with  Tα1②  and 
synthetic Tα1, the proliferation of all tumor cells was 
significantly  inhibited,  and  showed  the 
dose-dependent  effect.  As  shown  in  Fig.3,  HL60 
[IC50(Tα1) =318.75 μg/ml, IC50(Tα1②) =204.9μg/ml 
],  M1  [IC50(Tα1)  =385.05  μg/ml,  IC50(Tα1②) 
=182.7μg/ml],  S180  [IC50(Tα1)  =495.9μg/ml, 
IC50(Tα1②)  =239.4μg/ml],  and  B16  [IC50(Tα1) 
=426.3μg/ml, IC50(Tα1②) =230.4μg/ml ] displayed 
relatively  low  IC50  values  compared  with  HepG-2 
[IC50(Tα1) =596μg/ml, IC50(Tα1②) =376.5μg/ml ]. 
Effects of Tα1② treatment on cell cycle pro-
gression and apoptosis in B16 cells 
To  elucidate  potential  cellular  mechanisms  of 
Tα1②-induced growth inhibition, we examined the 
cell cycle progress and cell apoptosis by flow cytom-
etry. Tα1② at a concentration of 150μg/ml resulted in 
the decreasing the proportion of cells in the S phase 
after 16h of exposure (Fig.4A). To assess the effects of 
Tα1②  on  induction  of  B16  cell  apoptosis,  we  per-
formed flow cytometry after 16 h of treatment with150 
μg/ml,  300μg/ml  Tα1②  and  Tα1.  Flow  cytometric 
analysis showed both Tα1② and Tα1② can induce 
apoptosis  compared  with  the  control  group  in  a 
dose-dependent  manner  (Fig.4B).  Evaluation  of 
apoptosis  by  TUNEL  assay  showed  that  Tα1②  in-
duced a higher apoptotic rate in B16 cells compared 
with Tα1 at both doses (17.45±2.56% vs. 9.42±2.27% 
for 150μg/ml and 32.72±3.38 % vs. 19.58±2.31% for 
300μg/ml).  The  altered  cell  cycle  and  increased 
apoptosis may be the mechanisms against the prolif-
erative action of Tα1② in B16 cells in vitro. Int. J. Biol. Sci. 2011, 7 
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Ta1② inhibited the growth of tumor in the B16 
bearing mice 
To evaluate the bioactivity of Tα1② further, we 
observed the anti-tumor ability of Tα1② in the tu-
mor-bearing mice in vivo. In a randomized, controlled 
study, high dose of Tα1② and synthesized Tα1 were 
given to B16 bearing mice. Our data showed that the 
treatment of Tα1② (high dose=16mg/Kg/day, mid-
dle dose =8mg/Kg/day) for 12 days led to retarded 
tumor  growth  (Fig.5A)  and  reduced  tumor  weight 
(Fig.5B)  compared  to  control  group(P＜0.05).  This 
anti-tumor effect is more evident in initial stages of 
tumor growth. Tα1 at the dose of 8mg/Kg/day did 
not  show any  statistical  significance  (P=0.755)  com-
pared  to  the  control  group.  These  results  show  the 
activity of Tα1② in vivo is also more effective than 
the synthesized Tα1. 
 
 
 
 
 
 
Figure 3 Inhibitory effect of Tα1② on tumor cell lines. Cultured cells (5×10
3 cells/well) were exposed to various 
concentrations ofTα1 andTα1② (37.5μg/ml, 75μg/ml, 150μg/ml, 300μg/ml and 600μg/ml) for 24 h. Cell proliferation 
was determined by the MTT viability assay. The assays were repeated in triplicate. The data were expressed as the 
mean± (SD) of groups consisting of four observations. (A) Inhibition curve of HL60; (B) Inhibition curve of S180; (C) 
Inhibition curve of Hep-G2; (D) Inhibition curve of M1; (E) Inhibition curve of B16; (F) IC50 of Tα1 and Tα1② for 
different cell lines. (**P<0.01, *P<0.05) Int. J. Biol. Sci. 2011, 7 
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Figure 4 Effect of Tα1② on cell cycle progression and apoptosis in B16 cells. (A)Cultured B16 cells were exposed to 
150μg/ml Tα1 andTα1② for 16 h then acquired and the percentage of cells in each stage of the cell cycle was an-
alyzed. ⅰ.control group, ⅱ. 150μg/ml Tα1 group, ⅲ. 150μg/ml Tα1② group. Proportion of cells in the G1, S, and G2 
phases and apoptosis was calculated using the Cell Quest software. (B) Detection of apoptosis through annexin V and 
PI staining. ⅰ.control group, ⅱ. 150μg/ml Tα1 group, ⅲ. 150μg/ml Tα1② group, ⅳ.390μg/ml Tα1 group,ⅴ
.300μg/ml Tα1② group. (C) TUNEL assay comparison-The apoptosis index (AI) detected. Data are represented as 
mean ± SD. * and** showed p<0.05 and p<0.01 for n=3 triplicate after 16 hours of treatment with different concen-
trations PBS, Tα1 and Tα1② using TUNEL assay. 
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Figure 5.Tα1② inhibited the growth of tumor in the B16 bearing mice. C57BL/6 mice were challenged subcutane-
ously with B16 melanoma cells rearward for 10 days, followed by administration with synthesizedTα1 and different 
doses of Tα1② for another twelve days. Then the mice were executed and the tumor tissue was dissected and 
weighed. The data were expressed as the mean± (SD) of groups consisting of four observations. (A) Tumor volume 
measurement. B) Tumor weight of different groups, (*P<0.05). (C) Picture of isolated tumors. 
 
 
Discussion 
Previous  studies  have  confirmed  the  immu-
no-modulating  effects  of  Tα1  when  it  was  used  in 
combination  with  cytokines  and  chemotherapy, 
which was effective in inhibiting tumor growth and 
controlling infective  diseases,  particularly in  an im-
munocompromised host (31).  
 However, the Tα1 used in clinics is mainly pro-
duced by chemical synthesis and animal thymus ex-
traction (32-35). The amount of Tα1 extracted from calf 
or porcine thymus is limited. In addition, the impurity 
and quality variation of extracted Tα1 also restricts its 
application. Tα1 from this source is often impure so 
that it may cause heterogeneous allergies. Although 
chemically synthesized Tα1 can reach a high level of 
purity, it is necessary to get rid of by-products at each 
step. Thus, its cost is very expensive (27). Prokaryotic 
expression systems allow for high expression of for-
eign genes and are widely used for producing large 
amounts of proteins or peptides. However, it is diffi-
cult to extract the micromolecular recombinant pep-
tide  from  fermentation  broth  when  Tα1  (3.1kDa)  is 
expressed alone. In this study, we designed a protein 
sequence of two repeats of Tα1, Tα1②, whose molec-
ular weight was doubled (about 6.3kDa). A linker GS 
(Gly-Ser) was inserted between two repeats of Tα1. 
The flexibility and simple structure of GS linker may 
help  the  two  monomer  Tα1  peptides  to  keep  their 
conformation and function and also adds flexibility to 
the expressed protein. 
Active Tα1② was successfully expressed in E.coli 
suggesting that our design was reasonable. In addi-
tion, unlike regular high expression of other proteins, 
no inclusion bodies were found during the E.coil ex-
pression period, making it easier to purify the recom-
binant protein. Some of the known biological effects 
of  Tα1  include  enhanced  T-cell,  dendritic  and  anti-
body responses, chemo-protection properties, modu-
lation of cytokine and chemokine production, and the 
ability to block steroid-induced apoptosis of thymo-
cytes (36). In this study, we discarded the widely used 
heat treatment (29), though it is of great help to re-
move most miscellaneous proteins. We used ammo-
nium sulfate precipitation instead of heat treatment to 
avoid  possible  adverse  effects  on  the  bioactivity  of 
Tα1② protein caused by heat denaturation. 
Natural  Tα1  can  stimulate  the  proliferation  of 
splenic lymphocytes of mice. Consequently, we eval-
uated the capability of Tα1② to stimulate the prolif-
eration of mouse spleen lymphocytes after Tα1②was 
purified.  The  result  showed  that  the  Tα1②  was  of 
much stronger ability to promote proliferation than 
synthetic  Tα1.  A  possible  explanation  for  this  phe-
nomenon is that the conformation of the former might 
have stronger affinity with the Tα1 receptor compared 
with the latter. Tα1② may promote receptor dimeri-
zation better than the monomer.  Int. J. Biol. Sci. 2011, 7 
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Tα1  is  believed  to  augment  an  anti-tumor  im-
mune  response  by  activation  of  specific  signaling 
pathways  in  lymphoid  cells,  Firstly,  Tα1  has  been 
shown to increase lymphocytic infiltration to sites of 
disease, an effect which may be facilitated by the re-
lease  of  certain  chemokines  stimulated  by  Tα1.  Se-
cond, Tα1 mediates maturation and differentiation of 
dendritic  cells  which  synthesizes  specific  cytokines 
leading  to  an  increase  in  anti-tumor  T-cells.  An-
ti-melanoma  T-cells  have  been  shown  to  correlate 
with tumor regression and improve survival of pa-
tients with melanoma (36). Evidence showed that Tα1 
can  significantly  suppress  proliferation  and  induce 
apoptosis in many tumor cell lines, suggesting that 
Tα1 was a potent therapeutic agent for some kinds of 
malignant tumors (9, 11). Thus, we compared the ef-
fect of Tα1② and synthetic Tα1on tumor cell lines. The 
data showed that the 5 tumor cell lines (HL60, M1, 
S180, B16 and Hep-G2) were more sensitive to Tα1② 
and the effect of Tα1② on the tumor cell lines was 
much higher than Tα1. More significant cycle arrest 
and increase in apoptosis was induced after B16 cells 
exposed to Tα1② compared to Tα1. Ta1② inhibited 
the growth of tumor in the B16 bearing mice. The ac-
tivity of Tα1② in vivo is also more effective than the 
synthesized Tα1. These effects were attributed to be 
mediated by stimulation of the host immune response 
and direct suppression of proliferation and induction 
of apoptosis in some cancer cell lines. Therefore, the 
anti-tumor mechanism and signal pathway remains to 
be explained further. We are working on further dis-
cussion of its in vivo efficacy and interaction. Above 
all, our data indicated that the Tα1② we engineered 
with stronger bioactivity may be a good candidate for 
tumor therapy. 
Conclusion 
We developed a strategy for expression and pu-
rification of Tα1②. The final yields were 4.5mg puri-
fied protein per gram of cell paste. The purity of the 
protein was higher than 95%. This is the first report on 
successful expression of recombinant Tα1 with higher 
bioactivity than the commercial Tα1. Our study sug-
gests that this new purification protocol provides a 
cost effective and an efficient way to produce large 
quantities  of  high  purity  recombinant  Tα1②  which 
will greatly enhance the development and therapeutic 
application of this biologically potent molecule. 
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